Florian Brand, atai Life Sciences CEO
March 27, 2024 07:19 AM EDT
R&D

Atai Life Sci­ences spot­lights ear­ly de­pres­sion da­ta for psy­che­del­ic ahead of big read­out

Amber Tong

Less than two months af­ter bet­ting $50 mil­lion on Beck­ley Psytech’s psy­che­del­ic drugs, atai Life Sci­ences has shared ini­tial Phase 2a re­sults for one can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times